{
    "clinical_study": {
        "@rank": "58660", 
        "arm_group": {
            "arm_group_label": "Intramuscular seasonal trivalent inactivated influenza vaccine", 
            "arm_group_type": "Experimental", 
            "description": "The single arm of the study will consist of two cohorts: MELAS volunteers between 13-60 years for  OR  adult control volunteers between 18-65 years of age. Control volunteers will be age-matched +/-5 years to enrolled MELAS volunteers. If the MELAS volunteer has diabetes and uses insulin daily, their control will be an adult with diabetes who uses insulin daily.\nBoth cohorts will receive the same treatment: a single vaccination with FDA-licensed intramuscular seasonal trivalent inactivated influenza vaccine (TIV)."
        }, 
        "brief_summary": {
            "textblock": "This pilot clinical study, funded by the National Institutes of Health, will evaluate the\n      safety and metabolic responses to a licensed inactivated seasonal influenza vaccine (TIV).\n      This single arm study will consist of two cohorts: MELAS syndrome volunteers (a specific\n      identified disorder of mitochondrial dysfunction: mitochondrial encephalopathy, lactic\n      acidosis, and stroke-like episodes) between 13-60 years for OR adult control volunteers\n      between 18-65 years of age. Both cohorts will receive the same treatment: a single\n      vaccination with an FDA-licensed intramuscular seasonal trivalent inactivated influenza\n      vaccine (TIV)."
        }, 
        "brief_title": "Responses to Influenza Vaccine in Patients With Mitochondrial Disorders (MELAS)", 
        "completion_date": {
            "#text": "March 2012", 
            "@type": "Actual"
        }, 
        "condition": "MELAS Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "MELAS Syndrome", 
                "Mitochondrial Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "Mitochondrial disease constitutes the most common neurometabolic disease of childhood with\n      an estimated minimal lifetime risk of developing this disorder of 1 in 5000 live births.\n\n      This pilot study will for the first time prospectively assess the safety of seasonal flu\n      immunization in a subgroup of patients with MELAS syndrome. Comparing their responses to\n      those of healthy young control volunteers will provide new information about the safety and\n      immunogenicity of flu vaccination in this important sub-population and help guide the design\n      of future studies that can be carried out in younger children.\n\n      All participants will receive a single administration of a licensed influenza vaccine.\n      Prior to vaccination, participants will provide information regarding health history and\n      responses to health questionnaires.  Vital signs will be assessed.  A blood sample and urine\n      specimen will be collected prior to vaccination, and at 6 hours, 5-7 days and 26-30 days\n      post-immunization.  Volunteers will be asked to keep a diary of symptoms post-vaccination."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:Inclusion criteria include:\n\n          -  Age between 13-60 years for MELAS volunteers OR age between 18-65 years for adult\n             control volunteers. Control volunteers will be age-matched +/-5 years to enrolled\n             MELAS volunteers. If the MELAS volunteer has diabetes and uses insulin daily, their\n             control will be an adult with diabetes who uses insulin daily.\n\n          -  General good health at time of enrollment\n\n          -  Willing and able to sign Informed Consent\n\n          -  Available for follow-up for the planned duration of the study\n\n          -  Acceptable medical history by screening evaluation and brief clinical assessment\n\n          -  All female participants of childbearing potential must use an acceptable method of\n             contraception and not become pregnant for the duration of the clinical phase of the\n             study (approximately 1 month to completion of Visit 4). (Acceptable contraception may\n             include but is not limited to implants, injectables, combined oral contraceptives,\n             effective intrauterine devices (IUDs), sexual abstinence, or a vasectomized partner).\n\n        Exclusion Criteria:Exclusion criteria will include:\n\n          -  Allergy to egg or egg products or allergy to vaccine components, including thimerosal\n\n          -  Active systemic or serious concurrent illness, including febrile illness, within the\n             3 days prior to study vaccination\n\n          -  History of immunodeficiency, known or suspected impairment of immunologic function,\n             including, but not limited to, clinically significant liver disease, moderate to\n             severe renal disease, or any other chronic disorder which, in the opinion of the\n             investigator, might jeopardize volunteer safety or compliance with the protocol.\n\n          -  Blood pressure >150 systolic or >95 diastolic at Visit 1.\n\n          -  Hospitalization in the past year for congestive heart failure or emphysema.\n\n          -  History of chronic Hepatitis B or C.\n\n          -  Recent or current use of immunosuppressive medication, including glucocorticoids\n             (corticosteroid nasal sprays are permissible).\n\n          -  Malignancy, other than squamous cell or basal cell skin cancer (includes solid tumors\n             such as breast cancer or prostate cancer with recurrence in the past year, and any\n             hematologic cancer such as leukemia).\n\n          -  Autoimmune disease (including rheumatoid arthritis treated with immunosuppressive\n             medication such as Plaquenil, methotrexate, prednisone, Enbrel) which, in the opinion\n             of the investigator, might jeopardize volunteer safety or compliance with the\n             protocol.\n\n          -  History of blood dyscrasias, renal disease, or hemoglobinopathies requiring regular\n             medical follow up or hospitalization during the preceding year\n\n          -  Receipt of blood or blood products within the past 6 months\n\n          -  Medical or psychiatric condition or occupational responsibilities that preclude\n             subject compliance with the protocol\n\n          -  Inactivated vaccine 14 days prior to vaccination or live, attenuated vaccine within\n             60 days of vaccination\n\n          -  History of Guillain-Barr\u00e9 Syndrome\n\n          -  Pregnant or lactating woman\n\n          -  Use of investigational agents within 30 days prior to enrollment\n\n          -  Donation of the equivalent of a unit of blood within 6 weeks prior to enrollment\n\n          -  Any condition which, in the opinion of the investigator, might interfere with\n             volunteer safety, study objectives or the ability of the participant to understand or\n             comply with the study protocol."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "13 Years"
        }, 
        "enrollment": {
            "#text": "21", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01831934", 
            "org_study_id": "SU-18615", 
            "secondary_id": "R21HD061709-01A1"
        }, 
        "intervention": {
            "arm_group_label": "Intramuscular seasonal trivalent inactivated influenza vaccine", 
            "description": "FDA-licensed seasonal influenza vaccine", 
            "intervention_name": "Intramuscular seasonal trivalent inactivated influenza vaccine", 
            "intervention_type": "Biological", 
            "other_name": "Fluzone (IM)"
        }, 
        "is_fda_regulated": "Yes", 
        "keyword": "Mitochondrial Disorder; Immune Response; Influenza Vaccine", 
        "lastchanged_date": "May 7, 2014", 
        "link": [
            {
                "description": "Stanford-LPCH Vaccine Program website for clinical trials", 
                "url": "http://vaccines.stanford.edu/clinical_trials.html"
            }, 
            {
                "description": "United Mitochondrial Disease Foundation website", 
                "url": "http://www.umdf.org/site/c.otJVJ7MMIqE/b.5693191/k.7EC3/Clinical_Trials__Studies.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Stanford", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94305"
                }, 
                "name": "Stanford University School of Medicine"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Metabolic and Immune Responses to TIV in Patients With Mitochondrial Disease", 
        "overall_official": [
            {
                "affiliation": "Stanford University", 
                "last_name": "Cornelia L Dekker, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Stanford University", 
                "last_name": "Gregory M Enns, MBChB", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "We will measure solicited local and systemic adverse events and SAEs for 1 month following immunization", 
            "measure": "Clinical safety of TIV vaccine", 
            "safety_issue": "Yes", 
            "time_frame": "Day 0 to Day28"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01831934"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Stanford University", 
            "investigator_full_name": "Cornelia L. Dekker", 
            "investigator_title": "Professor, Pediatrics", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Intracellular ROS (iROS) will be measured by established protocols using the fluorescent dye DHR123 (Dihydrorhodamine 123).\nIntracellular RNS (iRNS) will be measured by established protocols using the fluorescent dye DAF-FM, DA (4-amino-5methylamino-2',7'-difluorofluorescein, diacetate)", 
                "measure": "Measurement of intracellular ROS and RNS by Hi-D FACS", 
                "safety_issue": "Yes", 
                "time_frame": "Day 0 to Day 28"
            }, 
            {
                "description": "This method relies on the ability of intracellular glutathione S-transferases to tag GSH to bimane to yield a bimane-GS conjugate that fluoresces at 440 nm.", 
                "measure": "Measurement of intracellular glutathione by Hi-D FACS (CD4 and CD8 T cells) and tandem mass spectrometry (whole blood)", 
                "safety_issue": "Yes", 
                "time_frame": "Day 0-Day 28"
            }, 
            {
                "description": "We will conduct a comprehensive analysis of serum cytokines, white blood cell subsets, gene expression and influenza-specific antibody and T cell responses in patients with mitochondrial dysfunction vs. controls", 
                "measure": "Comprehensive immune response profile to influenza", 
                "safety_issue": "No", 
                "time_frame": "Day 0 to Day 28"
            }
        ], 
        "source": "Stanford University", 
        "sponsors": {
            "collaborator": {
                "agency": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Stanford University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2010", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}